Hodgkin Lymphoma — Variants & evidence

Hodgkin Lymphoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

2 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EP300 G1506V1
Unspecified therapy	Predictive	B	Does Not Support N/A	3	rejected	EID7234 This missense variant is located in Histone acetyltransferases domain of p300 protein, which has been reported as association with Hodgkin's Lymphoma according to Cancer Cell Line Encyclopedia (CCLE) … (full text at CIViC) PMID 26124919 · Haery et al., 2015 · Open in CIViC	civic
JAK2 Overexpression1
(prognostic)	Prognostic	B	Supports Better Outcome	2	submitted	EID9776 In a phase II study of JAK2 inhibitor ruxolitinib, patients with advanced relapsed or refractory Hodgkin lymphoma examined potential JAK2 amplification in 12 patients which found JAK1 amplification to… (full text at CIViC) PMID 29351986 · Van Den Neste et al., 2018 · Open in CIViC	civic

Data updated 21 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.